BioSpace News Archive

I-Mab (the “Company”) (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced positive topline results from its regional multi-center, randomized, double-blind and placebo-controlled phase 2 study

GT Biopharma, Inc. (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company’s proprietary natural killer (NK) cell engager, TriKE™ protein biologic technology platform, today announced the appointment of Gregory Berk, M.D., to the position of Chief Medical Officer

- Sanofi is the only company to leverage its manufacturing capacity and expertise to support three different COVID-19 vaccines to support the global supply of vaccines and help address the pandemic - Sanofi to manufacture up to 200 million doses of Moderna’s vaccine in the U.S. starting in September 2021

- Proposed merger with Leading Biosciences, Inc. expected to close on or about Tuesday, April 27th, 2021

Daré Bioscience, Inc. (NASDAQ:DARE), a leader in women’s health innovation, today announced that data from the DARE-BVFREE Phase 3 study of DARE-BV1, a thermosetting vaginal gel for the treatment of bacterial vaginosis, will be presented at the 2021 American College of Obstetricians and Gynecologists (ACOG) Annual Clinical and Scientific Meeting. The meeting will be conducted virtually from April 30 - May 2, 2021.

Semler Scientific, Inc. (OTCQB: SMLR), a company that provides technology solutions to improve the clinical effectiveness and efficiency of healthcare providers, today announced that it will report financial results for the first quarter ended March 31, 2021 after the close of U.S. financial markets on Monday, May 3, 2021 .

Preclinical data demonstrated broad anti-tumor effect of BND-22 through the targeting of ILT2-mediated “do not eat me” signals in macrophages and by activating NK and CD8+ lymphocytes

InterVenn Biosciences today announced additions to the Company’s executive team in the month of April. Stephana Patton, Ph.D., J.D. joins InterVenn as Chief Legal Officer (CLO).

VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced its abstract featuring data from PROTECT, a pivotal Phase 3 immunogenicity and safety study evaluating the Company’s 3-antigen prophylactic hepatitis B (HBV) vaccine candidate, has been accepted for oral presentation at the National Foundation for Infectious Diseases

Hari Kumar, former CEO of Adheron Therapeutics, Inc. appointed Chairman of the Board of Directors Thierry Fumeaux, MD, former member of Swiss National Covid Taskforce, joined Kinarus as new Chief Medical Officer